Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and treatment.